Moderna Announces Interim Results from Phase 1 Study Vaccine Against COVID-19
(July 17, 2020) – In an interim analysis published in the New England Journal of Medicine
July 14, Moderna published the preliminary results of its COVID-19 vaccine
(mRNA-1273). The vaccine was given in two doses 28 days apart across three dose levels (25, 100, 250 µg) in 45 healthy adult participants ages 18-55 years, and reports results through Day 57. Results from participants in the initial dose cohorts who received both vaccinations reaffirm the positive interim data assessment announced on May 18 and show mRNA-1273 induced rapid and strong immune responses against SARS-CoV-2. The study was led by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.